Construction and Immunogenicity of Recombinant Swinepox Virus Expressing Outer Membrane Protein L of Salmonella = Construction and Immunogenicity of Recombinant Swinepox Virus Expressing Outer Membrane Protein L of Salmonella

다국어 초록 (Multilingual Abstract)

Salmonella spp. are gram-negative flagellated bacteria that cause a variety of diseases in humans and animals, ranging from mild gastroenteritis to severe systemic infection. To explore development of a potent vaccine against Salmonella infections, the gene encoding outer membrane protein L (ompL) was inserted into the swinepox virus (SPV) genome by homologous recombination. PCR, western blot, and immunofluorescence assays were used to verify the recombinant swinepox virus rSPV-OmpL. The immune responses and protection efficacy of rSPV-OmpL were assessed in a mouse model. Forty mice were assigned to four groups, which were immunized with rSPV-OmpL, inactive Salmonella (positive control), wildtype SPV (wtSPV; negative control), or PBS (challenge control), respectively. The OmpLspecific antibody in the rSPV-OmpL-immunized group increased dramatically and continuously over time post-vaccination, and was present at a significantly higher level than in the positive control group (p < 0.05). The concentrations of IFN-γ and IL-4, which represent Th1-type and Th2-type cytokine responses, were significantly higher (p < 0.05) in the rSPVOmpL- vaccinated group than in the other three groups. After intraperitoneal challenge with a lethal dose of Salmonella typhimurium CVCC542, eight out of ten mice in the rSPV-OmpLvaccinated group were protected, whereas all the mice in the negative control and challenge control groups died within 3 days. Passive immune protection assays showed that hyperimmune sera against OmpL could provide mice with effective protection against challenge from S. typhimurium. The recombinant swinepox virus rSPV-OmpL might serve as a promising vaccine against Salmonella infection.

참고문헌 (Reference)

1 Draper SJ, "Viruses as vaccine vectors for infectious diseases and cancer" 8 : 62-73, 2010

2 De Ridder L, "Use of a live attenuated Salmonella enterica serovar Typhimurium vaccine on farrow-to-finish pig farms" 202 : 303-308, 2014

3 Majowicz SE, "The global burden of nontyphoidal Salmonella gastroenteritis" 50 : 882-889, 2010

4 Afonso CL, "The genome of swinepox virus" 76 : 783-790, 2002

5 Benschop J, "Temp oral and longitudinal analysis of Danish Swine Salmonellosis Control Programme data: implications for surveillance" 136 : 1511-1520, 2008

6 Moorkamp L, "Swinepox - skin disease with sporadic occurrence" 115 : 162-166, 2008

7 Trip athy DN, "Swinep ox virus as a vaccine vector for swine pathogens" 41 : 463-480, 1999

8 Song J, "Structure and function of the Salmonella Typhi chimaeric A(2)B(5) typhoid toxin" 499 : 350-354, 2013

9 Yang TC, "Screening of the Salmonella paratyphi A CMCC 50973 strain outer membrane proteins for the identification of potential vaccine targets" 5 : 78-83, 2012

10 Strugnell RA, "Salmonella vaccines: lessons from the mouse model or bad teaching" 17 : 99-105, 2014

11 Winslow BJ, "Replication and expression of a swinepox virus vector delivering feline leukemia virus Gag and Env to cell lines of swine and feline origin" 98 : 1-15, 2003

12 Barcena J, "Recombinant swinepox virus expressing beta-galactosidase: investigation of viral host range and gene expression levels in cell culture" 243 : 396-405, 1998

13 Zhang Y, "Projected burden of disease for Salmonella infection due to increased temperature in Australian temperate and subtropical regions" 44 : 26-30, 2012

14 Pantaleo G, "Poxvirus vector-based HIV vaccines" 5 : 391-396, 2010

15 Ruggeri J, "Parenteral administration of attenuated Salmonella Typhimurium DeltaznuABC is protective against salmonellosis in piglets" 32 : 4032-4038, 2014

16 Murakami S, "Occurrence of swine salmonellosis in postweaning multisystemic wasting syndrome (PMWS) affected pigs concurrently infected with porcine reproduction and respiratory syndrome virus (PRRSV)" 68 : 387-391, 2006

17 Yamanouchi K, "New approaches to the development of virus vaccines for veterinary use" 17 : 641-653, 1998

18 Hong EH, "Intratumoral injection of attenuated Salmonella vaccine can induce tumor microenvironmental shift from immune suppressive to immunogenic" 31 : 1377-1384, 2013

19 Okamura M, "Immunization with outer membrane protein A from Salmonella enterica serovar Enteritidis induces humoral immune response but no protection against homologous challenge in chickens" 91 : 2444-2449, 2012

20 Yang Y, "Identification and characterization of OmpL as a potential vaccine candidate for immune-protection against salmonellosis in mice" 31 : 2930-2936, 2013

21 Penha Filho RA, "Humoral and cellular immune response generated by different vaccine programs before and after Salmonella Enteritidis challenge in chickens" 30 : 7637-7643, 2012

22 DasSarma P, "Haloarchaeal gas vesicle nanoparticles displaying Salmonella SopB antigen reduce bacterial burden when administered with live attenuated bacteria" 32 : 4543-4549, 2014

23 Sundara Baalaji N, "Functional assay of Salmonella typhi OmpC using reconstituted large unilamellar vesicles: a general method for characterization of outer membrane proteins" 88 : 1419-1424, 2006

24 Winslow BJ, "Feline B7.1 and B7.2 proteins produced from swinepox virus vectors are natively processed and biologically active: potential for use as nonchemical adjuvants" 111 : 1-13, 2005

25 Cao J, "Enhanced protection against pneumococcal infection elicited by immunization with the combination of PspA, PspC, and ClpP" 25 : 4996-5005, 2007

26 Poulet H, "Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform" 25 : 5606-5612, 2007

27 Nanton MR, "Cutting edge: B cells are essential for protective immunity against Salmonella independent of antibody secretion" 189 : 5503-5507, 2012

28 Hahn J, "Construction of recombinant swinepox viruses and expression of the classical swine fever virus E2 protein" 93 : 49-56, 2001

29 Hamid N, "Characterization of an outer membrane protein of Salmonella enterica serovar Typhimurium that confers protection against typhoid" 15 : 1461-1471, 2008

30 Abd El Ghany M, "Candidate live, attenuated Salmonella enterica serotype Typhimurium vaccines with reduced fecal shedding are immunogenic and effective oral vaccines" 75 : 1835-1842, 2007

31 Paoletti E, "Applications of pox virus vectors to vaccination: an update" 93 : 11349-11353, 1996

32 Ghosh S, "An adhesion p rotein of Salmonella enterica serovar Typhi is required for pathogenesis and potential target for vaccine development" 108 : 3348-3353, 2011

33 Lin HX, "A novel vaccine against porcine circovirus type 2 (PCV2) and Streptococcus equi ssp . zooepidemicus (SEZ) co-infection" 171 : 198-205, 2014

34 Lin HX, "A novel p vaccine against Streptococcus equi ss . zooepidemicus infections: the recombinant swinepox virus expressing Mlike protein" 29 : 7027-7034, 2011

35 Mathur R, "A mouse model of Salmonella typhi infection" 151 : 590-602, 2012